SETD7 and prostate cancer: Similarly, downregulation of SET7/9 in LNCaP prostate cancer cells reduced JMJD2A methylation, albeit to a lesser degree (Supplemental Figure 1B); this may be because residual SET7/9 in respective shRNA expressing LNCaP cells was still sufficient to methylate a large fraction of JMJD2A, or this may indicate the presence of another methyltransferase(s) in LNCaP cells capable of methylating JMJD2A.